13 reports

Nicotine gum can be used regularly (one piece of gum every ##-## hours for the first ## weeks, followed by one piece every ##-## hours for ## weeks, and then one piece every ##-## hours for ## weeks).

  • Smoking Cessation
  • United States
  • World
  • GlaxoSmithKline plc
  • Novartis AG

Apart from TMD, excessive chewing can cause gastrointestinal problems.

  • Smoking Cessation
  • World
  • Market Size
  • Mondelez International, Inc.
  • Wrigley, S.A.

You can easily book an appointment with one online.

  • Smoking Cessation
  • GlaxoSmithKline plc
  • ITC Limited
  • Pfizer Inc.
  • Reynolds American Inc.
  • 2014

Over the past 38 years the U.S. Rx-to-OTC market has grown into a $7.8 billion market. This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, brand re-invention, consumer demand, and cost containment strategies. The U.S. market for Rx-to-OTC Switches encompasses a wide...

  • Smoking Cessation
  • United States
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • SMALL MOLECULES TO ANTAGONIZE CHRNA4 AND CHRNB2 FOR NICOTINE ADDICTION - DRUG PROFILE

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Smoking Cessation
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd
  • SMALL MOLECULES TO ANTAGONIZE CHRNA4 AND CHRNB2 FOR NICOTINE ADDICTION - DRUG PROFILE

MAR ##, 2015: SUVEN LIFE SECURES ONE (##) PRODUCT PATENT EACH IN EURASIA AND ISRAEL The U. S.

  • Psychotic Disorder
  • Smoking Cessation
  • United States
  • World
  • Product Initiative
  • SMALL MOLECULES TO ANTAGONIZE CHRNA4 AND CHRNB2 FOR NICOTINE ADDICTION - DRUG PROFILE

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Psychotic Disorder
  • Smoking Cessation
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd
  • SMALL MOLECULES TO ANTAGONIZE CHRNA4 AND CHRNB2 FOR NICOTINE ADDICTION - DRUG PROFILE

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Psychotic Disorder
  • Smoking Cessation
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd
  • NICOTINE - DRUG PROFILE

The company offers APIs in the therapeutic areas of antibiotic, oncology, cardiovascular, urology, gastrointestinal, antiviral and respiratory, among others.

  • Pharmaceutical
  • Smoking Cessation
  • United States
  • Product Initiative
  • Invion Limited
  • NICOTINE BITARTRATE - DRUG PROFILE

The company offers APIs in the therapeutic areas of antibiotic, oncology, cardiovascular, urology, gastrointestinal, antiviral and respiratory, among others.

  • Pharmaceutical
  • Smoking Cessation
  • Therapy
  • United States
  • Product Initiative
  • Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction - Drug Profile

The molecules developed by Companies in Phase II, Phase I, IND/ CTA Filed, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Pharmaceutical
  • Smoking Cessation
  • United States
  • World
  • Product Initiative

After one week, Group ## continued with daily SL BPN/ NX and Group ## with weekly CAM2038 for the following ## weeks (Phase ##).

  • Opioid
  • Smoking Cessation
  • United States
  • Product Initiative
  • Omeros Corporation
  • Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction

The molecules developed by Companies in Phase II, Phase I, IND/ CTA Filed, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Psychotic Disorder
  • Smoking Cessation
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd